» Articles » PMID: 32614392

Clinical Characteristics and Factors Associated With Long-Term Viral Excretion in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Single-Center 28-Day Study

Overview
Journal J Infect Dis
Date 2020 Jul 3
PMID 32614392
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Despite the ongoing spread of coronavirus disease 2019 (COVID-19), knowledge about factors affecting prolonged viral excretion is limited.

Methods: In this study, we retrospectively collected data from 99 hospitalized patients with coronavirus disease 2019 (COVID-19) between 19 January and 17 February 2020 in Zhejiang Province, China. We classified them into 2 groups based on whether the virus test results eventually became negative. Cox proportional hazards regression was used to evaluate factors associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) shedding.

Results: Among 99 patients, 61 patients had SARS-CoV-2 clearance (virus-negative group), but 38 patients had sustained positive results (virus-positive group). The median duration of SARS-CoV-2 excretion was 15 (interquartile range, 12-19) days among the virus-negative patients. The shedding time was significantly increased if the fecal SARS-CoV-2 RNA test result was positive. Male sex (hazard ratio [HR], 0.58 [95% confidence interval {CI}, .35-.98]), immunoglobulin use (HR, 0.42 [95% CI, .24-.76]), APACHE II score (HR, 0.89 [95% CI, .84-.96]), and lymphocyte count (HR, 1.81 [95% CI, 1.05-3.1]) were independent factors associated with a prolonged duration of SARS-CoV-2 shedding. Antiviral therapy and corticosteroid treatment were not independent factors.

Conclusions: SARS-CoV-2 RNA clearance time was associated with sex, disease severity, and lymphocyte function. The current antiviral protocol and low-to-moderate dosage of corticosteroid had little effect on the duration of viral excretion.

Citing Articles

Median duration and factors that influence the duration of symptom resolution in COVID-19 patients in Ethiopia: A follow-up study involving symptomatic cases.

Abrahim S, Tessema M, Ejeta E, Ahmed M, Defar A, Hussen A Lifestyle Med (Hoboken). 2024; 2(4):e46.

PMID: 38607830 PMC: 8646405. DOI: 10.1002/lim2.46.


Time to recovery and its determinant factors among patients with COVID-19 in Assosa COVID-19 treatment center, Western Ethiopia.

Kassie M, Gobena M, Alemu Y, Tegegne A Pneumonia (Nathan). 2023; 15(1):17.

PMID: 37925445 PMC: 10625712. DOI: 10.1186/s41479-023-00119-3.


Quantitative SARS-CoV-2 subgenomic RNA as a surrogate marker for viral infectivity: Comparison between culture isolation and direct sgRNA quantification.

Scutari R, Renica S, Cento V, Nava A, Sammartino J, Ferrari A PLoS One. 2023; 18(9):e0291120.

PMID: 37656746 PMC: 10473502. DOI: 10.1371/journal.pone.0291120.


Understanding the viral shedding time of Omicron variant BA.2 infection in Shanghai: A population-based observational study.

Lu Z, Kuang Z, Li B, Song Z, Huang L Heliyon. 2023; 9(6):e17173.

PMID: 37342569 PMC: 10277587. DOI: 10.1016/j.heliyon.2023.e17173.


Benefits of high-dose intravenous immunoglobulin on mortality in patients with severe COVID-19: An updated systematic review and meta-analysis.

Liu X, Zhang Y, Lu L, Li X, Wu Y, Yang Y Front Immunol. 2023; 14:1116738.

PMID: 36756131 PMC: 9900022. DOI: 10.3389/fimmu.2023.1116738.


References
1.
Lee N, Chan K, Hui D, Ng E, Wu A, Chiu R . Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004; 31(4):304-9. PMC: 7108318. DOI: 10.1016/j.jcv.2004.07.006. View

2.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199-1207. PMC: 7121484. DOI: 10.1056/NEJMoa2001316. View

3.
Sung J, Wu A, Joynt G, Yuen K, Lee N, Chan P . Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax. 2004; 59(5):414-20. PMC: 1746995. DOI: 10.1136/thx.2003.014076. View

4.
Min C, Cheon S, Ha N, Sohn K, Kim Y, Aigerim A . Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep. 2016; 6:25359. PMC: 4857172. DOI: 10.1038/srep25359. View

5.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View